> top > projects > Inflammaging > docs > PubMed:26978417 > annotations
Inflammaging  

PubMed:26978417 JSONTXT 2 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-167 Sentence denotes [Correction of an inflammatory process with an interleukin-1 inhibitor in the combination treatment of secondary osteoarthritis in the presence of comorbid condition].
T1 0-167 Sentence denotes [Correction of an inflammatory process with an interleukin-1 inhibitor in the combination treatment of secondary osteoarthritis in the presence of comorbid condition].
T2 168-172 Sentence denotes AIM:
T2 168-172 Sentence denotes AIM:
T3 173-365 Sentence denotes To enhance the efficiency of treatment in patients with secondary osteoarthritis (ОА) in the presence of comorbid condition, by using an interleukin-1 inhibitor (IL-1i) and laser therapy (LT).
T3 173-365 Sentence denotes To enhance the efficiency of treatment in patients with secondary osteoarthritis (ОА) in the presence of comorbid condition, by using an interleukin-1 inhibitor (IL-1i) and laser therapy (LT).
T4 366-387 Sentence denotes SUBJECTS AND METHODS:
T4 366-387 Sentence denotes SUBJECTS AND METHODS:
T5 388-559 Sentence denotes A total of 248 patients aged 38 to 65 years with RA and secondary OA who had predominantly Stage II in accordance with the Disease Activity Score 28 (DAS28) were examined.
T5 388-559 Sentence denotes A total of 248 patients aged 38 to 65 years with RA and secondary OA who had predominantly Stage II in accordance with the Disease Activity Score 28 (DAS28) were examined.
T6 560-635 Sentence denotes According to the received therapy, the patients were divided into 4 groups:
T6 560-635 Sentence denotes According to the received therapy, the patients were divided into 4 groups:
T7 636-704 Sentence denotes 1) IL-1i + LT + mrthotrexate (MT); 2) IL-1i + MT; 3) LT + MT; 4) MT.
T7 636-704 Sentence denotes 1) IL-1i + LT + mrthotrexate (MT); 2) IL-1i + MT; 3) LT + MT; 4) MT.
T8 705-896 Sentence denotes The efficiency of treatment was evaluated from changes in the KOOS (Knee injury and Osteoarthritis Outcome Score), DAS 28, IL-1, and cartilage oligomeric matrix protein (COMP) 6 months later.
T8 705-896 Sentence denotes The efficiency of treatment was evaluated from changes in the KOOS (Knee injury and Osteoarthritis Outcome Score), DAS 28, IL-1, and cartilage oligomeric matrix protein (COMP) 6 months later.
T9 897-905 Sentence denotes RESULTS:
T9 897-905 Sentence denotes RESULTS:
T10 906-1036 Sentence denotes There were statistically significant functional improvements in KOOS and DAS28 in Groups 1 and 2 patients with secondary OA in RA.
T10 906-1036 Sentence denotes There were statistically significant functional improvements in KOOS and DAS28 in Groups 1 and 2 patients with secondary OA in RA.
T11 1037-1119 Sentence denotes Clinical efficacy was confirmed by positive changes in serum IL-1 and COMP levels.
T11 1037-1119 Sentence denotes Clinical efficacy was confirmed by positive changes in serum IL-1 and COMP levels.
T12 1120-1131 Sentence denotes CONCLUSION:
T12 1120-1131 Sentence denotes CONCLUSION:
T13 1132-1369 Sentence denotes Incorporation of an IL-1i into a therapy regimen for secondary OA in RA patients during basic therapy could not only improve the functional status of patients, but also decrease activity of the underlying disease according to the DAS 28.
T13 1132-1369 Sentence denotes Incorporation of an IL-1i into a therapy regimen for secondary OA in RA patients during basic therapy could not only improve the functional status of patients, but also decrease activity of the underlying disease according to the DAS 28.